Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential deal value above $1.3 billion.

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a ...

On May 16, Eli Lilly and Company (NYSE ... on a computer terminal with a patient in the background. The collaboration complements Lilly's existing genetic hearing loss pipeline, including AK ...

Eli Lilly is strengthening its position in genetic medicine for hearing loss through a new collaboration with South Korea-based biotech Rznomics. The agreement, centred on the development of RNA ...

This partnership, which officials said has the potential to be the largest ever U.S. industry-academic agreement of its kind, ...

INDIANAPOLIS and WEST LAFAYETTE, May 9, 2025 — Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly’s planned ...

On May 16, Eli Lilly and ... while Lilly handles clinical development and commercialization using RNA editing, a reversible alternative to CRISPR. The collaboration complements Lilly’s existing ...

Eli Lilly and Co. and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly’s planned investment of up to $250 million in the collaboration over ...